Live Analyst Rating Changes 28472 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Kevin Fischbeck
BofA

Kevin Fischbeck

Bank of America Securities
Wall Street Analyst
★★☆☆☆
#2267
on 13Foresight · ranked by our own returns
54%
Success Rate
-10.0%
Average Return
37 of 68 calls profitable · -19.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 54% of Kevin Fischbeck's ratings turned a profit when each position was held for 2 year — averaging -10.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

37 Buy 30 Hold 30 Sell
Kevin's Stock Coverage 27 ratings · 2026-08-29
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return vs S&P 500 ⓘ
THC
Tenet Healthcare
 Aug 10, 2026 BUY Strong Buy
-11.0% avg upside
27 analysts
$295.00
10.50% Upside
 +3.0% ·
ARDT
Ardent Health Partners, Inc.
 Aug 10, 2026 SELL Buy
+27.0% avg upside
16 analysts
$10.00
8.78% Downside
 +1.0% ·
UHS
Universal Health
 Aug 10, 2026 SELL Buy
+14.3% avg upside
22 analysts
$170.00
1.01% Downside
 +0.1% ·
HCA
HCA Healthcare
 Aug 10, 2026 HOLD Buy
-3.1% avg upside
36 analysts
$425.00
1.75% Upside
 +1.3% ·
AMN
AMN Healthcare Services
 Aug 07, 2026 SELL Buy
+27.8% avg upside
14 analysts
 — +4.9% ·
HUM
Humana
 Aug 07, 2026 BUY Buy
+7.8% avg upside
34 analysts
$500.00
29.62% Upside
 +1.2% ·
DVA
DaVita
 Aug 05, 2026 SELL Buy
-4.7% avg upside
17 analysts
 — +7.9% ·
CI
Cigna
 Jul 30, 2026 BUY Strong Buy
+24.2% avg upside
29 analysts
$378.00
35.56% Upside
 -3.5% ·
CNC
Centene
 Jul 28, 2026 BUY Buy
+10.4% avg upside
29 analysts
$78.00
20.50% Upside
 +2.2% ·
MOH
Molina Healthcare
 Jul 23, 2026 BUY Buy
+18.7% avg upside
26 analysts
$260.00
29.91% Upside
 -0.8% ·
UNH
UnitedHealth
 Jul 17, 2026 BUY Strong Buy
+15.4% avg upside
36 analysts
$512.00
30.27% Upside
 -5.9% ·
ELV
Elevance Health
 Jul 16, 2026 BUY Strong Buy
+13.6% avg upside
33 analysts
$460.00
16.68% Upside
 +7.0% ·
ALHC
Alignment Healthcare
 Sep 09, 2025 BUY Strong Buy
+56.9% avg upside
19 analysts
$23.00
68.96% Upside
 -15.7% ·
AGL
Agilon Health
 Aug 05, 2025 SELL Buy
-27.6% avg upside
26 analysts
$32.50
64.90% Downside
 -336.3% ·
ACHC
Acadia Healthcare
 May 15, 2024 BUY Strong Buy
+41.7% avg upside
17 analysts
$90.00
215.15% Upside
 -62.5% ·
EHC
Encompass Health
 May 15, 2024 BUY Strong Buy
-6.4% avg upside
22 analysts
$95.00
21.31% Downside
 +25.1% ·
SGRY
Surgery Partners
 May 14, 2024 BUY Strong Buy
+62.5% avg upside
18 analysts
$40.00
192.26% Upside
 -46.3% ·
MD
Pediatrix Medical Group
 May 07, 2024 SELL Buy
-16.0% avg upside
14 analysts
$9.00
66.20% Downside
 -153.4% ·
CYH
Community Health
 Sep 05, 2023 HOLD Sell
+41.8% avg upside
18 analysts
$4.75
62.09% Upside
 -13.4% ·
CLOV
Clover Health Investments
 Aug 09, 2023 SELL Hold
-12.4% avg upside
9 analysts
$0.90
78.72% Downside
 -56.8% ·
OSCR
Oscar Health
 Jun 06, 2023 HOLD Buy
-27.8% avg upside
16 analysts
$8.75
71.33% Downside
 +73.5% ·
CSWC
Capital Southwest
 May 25, 2023 BUY Strong Buy
-7.2% avg upside
11 analysts
$22.00
13.65% Downside
 +41.0% ·
CVS
CVS Health
 Jan 09, 2023 BUY Strong Buy
+14.5% avg upside
39 analysts
$116.00
24.57% Upside
 -45.9% ·
OPCH
Option Care Health
 Jul 28, 2022 BUY Strong Buy
+22.6% avg upside
20 analysts
$39.00
63.15% Upside
 -8.2% ·
AHCO
AdaptHealth
 Jan 07, 2022 BUY Strong Buy
+105.0% avg upside
13 analysts
$30.00
418.18% Upside
 -67.4% ·
CHE
Chemed
 Jan 05, 2021 BUY Buy
+2.4% avg upside
5 analysts
$605.00
15.59% Upside
 -5.1% ·
BKD
Brookdale Senior Living
 Sep 06, 2019 SELL Strong Buy
+17.2% avg upside
11 analysts
$7.50
35.96% Downside
 +12.4% ·
🔒 22 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Kevin Fischbeck — Frequently Asked Questions
How accurate are Kevin Fischbeck's stock ratings?
Based on the calls 13Foresight could measure, about 57% of Kevin's ratings were profitable over a one-year hold, with an average return of -4.1% per rating, or -9.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Kevin ranked on 13Foresight?
Kevin Fischbeck is currently ranked #2267 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Kevin cover?
Kevin most recently has ratings on THC, ARDT, UHS, HCA, AMN, HUM, DVA, CI, CNC, MOH, UNH, ELV and 15 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.